For the month ended 30 September 2026, AIM Vaccine Co., Ltd. filed its statutory monthly return with Hong Kong Exchanges and Clearing Limited, reporting no changes to its share capital or issued share count.

AIM Vaccine’s registered share capital remained at RMB 1.23 billion, split between 507.67 million H shares and 718.89 million domestic shares, each with a par value of RMB 1. Both classes of shares were unchanged during the period.

Issued share capital also stayed constant: 507.67 million H shares are listed on the Hong Kong Stock Exchange (HKEX: 06660), while 718.89 million domestic shares are unlisted. The company held no treasury shares, and there were no issuances, repurchases, cancellations, or conversions during the month.

Management confirmed that the H-share public float met the HKEX’s 25% minimum threshold as of 30 September 2026.

No share options, warrants, convertible securities, other equity-linked instruments, or Hong Kong Depositary Receipts were outstanding or issued in the period. The filing, dated 5 October 2026, was signed by Company Secretary Liu Ling, who affirmed full compliance with applicable listing rules and regulatory requirements.